MYLK Antibody (MLJ-16): sc-69869

MYLK Antibody (MLJ-16) is a mouse monoclonal IgG1 antibody that detects myosin light chain kinase (MYLK) in human samples through western blotting (WB). MYLK is a crucial enzyme that plays a significant role in muscle contraction by phosphorylating myosin regulatory light chains, which facilitates the interaction between myosin and actin filaments, ultimately leading to contractile activity. This process is vital not only in smooth muscle but also in non-muscle and skeletal/cardiac muscle tissues, highlighting MYLK′s importance in various physiological functions. The MYLK gene encodes multiple isoforms, including those specific to smooth muscle and non-muscle tissues, as well as telokin, a unique C-terminal isoform that stabilizes unphosphorylated myosin filaments in smooth muscle. The presence of different isoforms allows for a diverse range of regulatory mechanisms in muscle contraction across various tissue types. Additionally, MYLK interacts with p21-activated kinases (PAKs), such as PAK1, which can inhibit MYLK activity and reduce myosin light chain phosphorylation, further emphasizing the intricate regulatory networks that govern muscle function. Anti-MYLK antibody (MLJ-16) serves as an essential tool for researchers studying muscle physiology and related disorders.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

MYLK Antibody (MLJ-16) References:

1. Hypermethylated FAM5C and MYLK in serum as diagnosis and pre-warning markers for gastric cancer.  |  Chen, L., et al. 2012. Dis Markers. 32: 195-202. PMID: 22377736
2. Mechanical Stress and Single Nucleotide Variants Regulate Alternative Splicing of the MYLK Gene.  |  Mascarenhas, JB., et al. 2017. Am J Respir Cell Mol Biol. 56: 29-37. PMID: 27529643
3. Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway.  |  Zhong, Z., et al. 2017. Cancer Lett. 403: 305-317. PMID: 28687357
4. The Splicing Factor hnRNPA1 Regulates Alternate Splicing of the MYLK Gene.  |  Mascarenhas, JB., et al. 2018. Am J Respir Cell Mol Biol. 58: 604-613. PMID: 29077485
5. Long noncoding RNA MYLK-AS1 promotes growth and invasion of hepatocellular carcinoma through the EGFR/HER2-ERK1/2 signaling pathway.  |  Liu, J., et al. 2020. Int J Biol Sci. 16: 1989-2000. PMID: 32398965
6. LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma.  |  Teng, F., et al. 2020. J Exp Clin Cancer Res. 39: 235. PMID: 33168027
7. SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK.  |  Shi, X., et al. 2022. Mol Oncol. 16: 2558-2574. PMID: 35278271
8. The m6A methyltransferase METTL3 promotes trophoblast cell invasion by regulating MYLK expression.  |  Zhao, J., et al. 2022. Placenta. 129: 1-6. PMID: 36170767
9. LncRNA MYLK antisense RNA 1 activates cell division cycle 42/Neutal Wiskott-Aldrich syndrome protein pathway via microRNA-101-5p to accelerate epithelial-to-mesenchymal transition of colon cancer cells.  |  Quan, ZH., et al. 2024. Kaohsiung J Med Sci. 40: 11-22. PMID: 37950620
10. IGF2BP3-mediated enhanced stability of MYLK represses MSC adipogenesis and alleviates obesity and insulin resistance in HFD mice.  |  Huang, X., et al. 2024. Cell Mol Life Sci. 81: 17. PMID: 38196046

The preferred MYLK antibody is MYLK Antibody (A-8): sc-365352.